NCT06808815View on ClinicalTrials.gov

A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis

PHASE1CompletedINTERVENTIONAL

Enrollment

104

Participants

Timeline

Start Date

September 22, 2021

Primary Completion Date

August 23, 2022

Study Completion Date

August 23, 2022

Conditions

Plaque Psoriasis

Interventions

DRUG

DC-806

administered orally.

OTHER

Placebo

administered orally.

Trial Locations (1)

M23 9QZ

The Medicines Evaluation Unit (MEU) Ltd., Manchester

All Listed Sponsors

lead

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

INDUSTRY

NCT06808815 - A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis | Biotech Hunter | Biotech Hunter